[1]任磊鹏,张新伟,王瑞洁,等.拓扑替康对裸鼠非小细胞肺癌的治疗效果及机制研究[J].陕西医学杂志,2022,51(6):676-679,701.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.008]
　REN Leipeng,ZHANG Xinwei,WANG Ruijie,et al.Therapeutic effect and mechanism of topotecan on non-small cell lung cancer in nude mice[J].,2022,51(6):676-679,701.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.008]
点击复制

拓扑替康对裸鼠非小细胞肺癌的治疗效果及机制研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年6期
页码:
676-679,701
栏目:
基础研究
出版日期:
2022-06-05

文章信息/Info

Title:
Therapeutic effect and mechanism of topotecan on non-small cell lung cancer in nude mice
作者:
任磊鹏1; 张新伟2; 王瑞洁3; 李 潜1; 孙党泽1; 刘玉钢1
(1.西安市胸科医院胸外科,陕西 西安 710100; 2.陕西省肿瘤医院胸外科,陕西 西安 710065; 3.西安市东方医院内科,陕西 西安710043)
Author(s):
REN Leipeng; ZHANG Xinwei; WANG Ruijie; LI Qian; SUN Dangze; LIU Yugang
(Department of Thoracic Surgery,Xi'an Chest Hospital,Xi'an 710100,China)
关键词:
非小细胞肺癌;  拓扑替康;  裸鼠;  半胱氨酸天冬氨酸蛋白酶-3;  血管内皮生长因子C;  基质金属蛋白酶-2
Keywords:
Non-small cell lung cancer;  Topotecan;  Nude mice;  Caspase-3;  Vascular endothelial growth factor C;  Matrix metalloproteinases-2
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.06.008
文献标志码:
A
摘要:
目的:探讨拓扑替康(TPT)对裸鼠非小细胞肺癌(NSCLC)的治疗效果及可能机制。方法:于每只裸鼠左侧腋部皮下注射0.2 ml H1993细胞悬浊液进行造模。将造模成功的裸鼠随机分成对照组(CG组)、TPT低剂量组(LG组)、TPT中剂量组(MG组)和TPT高剂量组(HG组),每组20只。TPT给药组以TPT灌胃,剂量依次为0.5、1.0、1.5 mg/(kg·d)。CG组裸鼠灌胃等量0.9%氯化钠溶液。每日1次,连续给药30 d。记录各组裸鼠的体重、死亡情况、肿瘤体积、瘤细胞凋亡率。检测裸鼠肿瘤组织中半胱氨酸天冬氨酸蛋白酶-3(Caspase-3)、Ki-67抗原(Ki-67)、血管内皮生长因子C(VEGFC)、基质金属蛋白酶-2(MMP-2)和胱抑素C的表达情况。结果:给药30 d时,LG组、MG组和HG组裸鼠体重明显高于CG组,死亡率明显低于CG组(均P<0.05)。与CG组比较,LG组、MG组和HG组裸鼠Ki-67、VEGFC、MMP-2、胱抑素C表达水平,以及肿瘤体积、细胞凋亡率显著降低,肿瘤抑制率和Caspase-3表达水平显著升高(均P<0.05)。结论:TPT可降低NSCLC移植瘤裸鼠的病死率,对NSCLC移植瘤具有较好的抑制作用,其机制可能与TPT增加H1993细胞Caspase-3蛋白表达,降低胱抑素C、Ki-67及MMP-2蛋白表达水平有关。
Abstract:
Objective:To investigate the therapeutic effect of topotecan(TPT)on non-small cell lung cancer(NSCLC)in nude mice and its possible mechanism.Methods: The model was established by subcutaneous injection of 0.2 ml H1993 cell suspension into the left axillary of each nude mouse.After successful modeling,nude mice were randomly divided into control group(CG group),TPT low dose group(LG group),TPT medium dose group(MG group)and TPT high dose group(HG group),with 20 mice in each group.TPT administration group was given TPT by gavage at doses of 0.5,1.0 and 1.5 mg/(kg·d),nude mice in CG group were gavaged with equal amounts of 0.9% sodium chloride solution,once daily for 30 days.Body weight,death,tumor volume and apoptosis rate of tumor cells were recorded.The expression of Caspase-3,Ki-67,VEGFC,MMP-2 and cystatin C in tumor tissues of nude mice were detected.Results:After 30 days of administration,the weight of nude mice in LG,MG and HG groups was significantly higher than that in CG group,and the mortality rate was significantly lower than that in CG group(all P<0.05).Compared with CG group,the expression levels of Ki-67,VEGFC,MMP-2,cystatin C,as well as tumor volume and apoptosis rate of nude mice in LG,MG and HG groups were significantly decreased,while the tumor inhibition rate and Caspase-3 expression level were significantly increased(all P<0.05).Conclusion:TPT can reduce the mortality of nude mice with NSCLC xenograft and has a good inhibitory effect on NSCLC xenograft.The mechanism may be related to the increase of Caspase-3 protein expression and the decrease of cystatin C,Ki-67 and MMP-2 proteins expression in H1993 cells.

参考文献/References:

[1] 苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15-21.
[2] 信 波,张开亮,宋晓鹏,等.雌激素受体β拮抗剂对非小细胞肺癌A549细胞增殖、迁移及侵袭能力的影响[J].陕西医学杂志,2020,49(10):1223-1227.
[3] 付雅敏,郭雅丽.支气管镜检查在周围型肺癌诊断中的临床价值[J].中国药物与临床,2020,20(17):2922-2924.
[4] 孙可雯.晚期肺癌患者采用糖皮质激素治疗对其生活质量的影响[J].中国药物与临床,2019,19(24):4313-4315.
[5] 叶 奇,梁应凤,郭姗姗,等.健脾益肾方对非小细胞肺癌细胞体外增殖凋亡作用的实验研究[J].陕西中医,2020,41(5):574-577.
[6] Frumovitz M,Munsell MF,Burzawa JK,et al.Combination therapy with topotecan,paclitaxel,and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix[J].Gynecol Oncol,2017,144(1):46-50.
[7] 张 良,刘显红,柳 影,等.三药联合化疗和单药拓扑替康二线治疗小细胞肺癌的疗效和安全性比较[J].中国肿瘤临床,2019,46(3):133-137.
[8] 朱 燕,石永进,赵玉亮,等.拓扑异构酶抑制剂通过ATM/ATR和NF-κB途径上调乳腺癌细胞MICA/B的表达[J].北京大学学报:医学版,2018,50(2):318-325.
[9] 吴 坤,皮国良.肺癌放射治疗的应用策略及研究进展[J].临床内科杂志,2020,37(2):78-81.
[10] 单一波,蒋薛伟,黄 斌,等.3D技术在早期肺癌围手术期的应用进展[J].中华胸心血管外科杂志,2020,36(7):434-437.
[11] 成 远,耿海云,华海清.阿帕替尼联合拓扑替康多线治疗铂类耐药复发性卵巢癌2例报告[J].肿瘤防治研究,2018,45(3):188-190.
[12] 刘大锐,李报春,李怀东.细胞凋亡核心基因Caspase家族的研究进展[J].中国医药导刊,2020,22(11):800-805.
[13] 肖丽娜,周先荣,张青华.Caspase-3蛋白在非小细胞肺癌中的表达及其与肿瘤细胞凋亡的关系[J].检验医学与临床,2019,16(14):2034-2036,2041.
[14] Prajna G,Jillian G,Josephine D,et al.STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells[J].Oncogene,2019,38(4):533-548.
[15] 刘长浩,刘宏旭.Vacquinol-1对非小细胞肺癌细胞增殖和凋亡的影响[J].现代肿瘤医学,2018,26(20):3177-3179.
[16] Lin L,Cheng J,Tang D,et al.The associations among quantitative spectral CT parameters,Ki-67 expression levels and EGFR mutation status in NSCLC[J].Scientific Reports,2020,10(1):3436.
[17] Previs RA,Armaiz-Pena GN,Lin YG,et al.Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent antiangiogenic activity in ovarian cancer[J].Molecular Cancer Therapeutics,2015,14(12):2677-2686.
[18] 郑 茜,刘远婷,丁甜甜,等.消积抑癌方对Lewis肺癌荷瘤小鼠MMP-2的影响[J].陕西中医,2021,42(7):844-848.
[19] 杨 丽,孙孟雄,陈丽华.参芪扶正注射液联合TC方案化疗对晚期卵巢癌肿瘤标志物、肿瘤血管生成因子及免疫相关因子的影响[J].解放军医药杂志,2020,32(10):79-83.
[20] Tao S,Yu J,Xu Y,et al.PC4 induces lymphangiogenesis dependent VEGF-C/VEGF-D/VEGFR-3 axis activation in lung adenocarcinoma[J].American Journal of Cancer Research,2015,5(6):1878-1889.
[21] 王总飞,杨慧远,刘先本,等.拓扑替康对非小细胞肺癌荷瘤小鼠存活和肿瘤细胞转移的影响及相关机制[J].癌症进展,2020,18(1):26-29,61.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(6):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(6):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(6):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(6):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(6):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(6):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(6):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2020SF-117)
更新日期/Last Update: 2022-06-06